NeoGenomics (NASDAQ:NEO) Lifted to “Buy” at BidaskClub

BidaskClub upgraded shares of NeoGenomics (NASDAQ:NEO) from a hold rating to a buy rating in a research report report published on Friday, BidAskClub reports.

Several other equities research analysts have also recently weighed in on the company. Needham & Company LLC reissued a buy rating and issued a $10.00 price target (down previously from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. Zacks Investment Research cut GENEL ENERGY PL/ADR from a buy rating to a hold rating in a research note on Tuesday, May 7th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $21.11.

NEO stock opened at $23.85 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.46. The business’s 50 day simple moving average is $22.80. NeoGenomics has a 1-year low of $11.05 and a 1-year high of $24.84. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of 183.46 and a beta of 0.78.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, April 30th. The medical research company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. NeoGenomics had a positive return on equity of 3.07% and a negative net margin of 0.14%. The firm had revenue of $95.60 million for the quarter, compared to analyst estimates of $89.71 million. During the same period in the prior year, the firm posted $0.04 EPS. The company’s revenue for the quarter was up 50.8% on a year-over-year basis. As a group, research analysts predict that NeoGenomics will post 0.18 EPS for the current fiscal year.

In related news, insider George Cardoza sold 151,676 shares of NeoGenomics stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $22.82, for a total transaction of $3,461,246.32. Following the sale, the insider now directly owns 452,507 shares in the company, valued at $10,326,209.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Bonello sold 7,200 shares of NeoGenomics stock in a transaction on Monday, May 6th. The stock was sold at an average price of $23.53, for a total value of $169,416.00. Following the sale, the insider now owns 13,935 shares in the company, valued at $327,890.55. The disclosure for this sale can be found here. Insiders sold 338,876 shares of company stock worth $7,674,362 in the last 90 days. Corporate insiders own 8.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. increased its position in NeoGenomics by 150.5% in the first quarter. BlackRock Inc. now owns 13,825,064 shares of the medical research company’s stock worth $282,861,000 after buying an additional 8,305,417 shares during the last quarter. Eagle Asset Management Inc. increased its position in NeoGenomics by 19.0% in the first quarter. Eagle Asset Management Inc. now owns 2,705,536 shares of the medical research company’s stock worth $55,355,000 after buying an additional 431,393 shares during the last quarter. Emerald Mutual Fund Advisers Trust increased its position in NeoGenomics by 2.3% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 1,875,759 shares of the medical research company’s stock worth $38,378,000 after buying an additional 41,390 shares during the last quarter. Granite Investment Partners LLC increased its position in NeoGenomics by 14.4% in the first quarter. Granite Investment Partners LLC now owns 1,764,090 shares of the medical research company’s stock worth $36,093,000 after buying an additional 221,850 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its position in NeoGenomics by 0.5% in the first quarter. Artisan Partners Limited Partnership now owns 1,487,720 shares of the medical research company’s stock worth $30,439,000 after buying an additional 7,233 shares during the last quarter. Institutional investors and hedge funds own 84.08% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Read More: Derivative

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.